Status:
COMPLETED
Extension Study Evaluating Etanercept in Ankylosing Spondylitis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study ev...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients who completed 16 weeks of treatment and have completed the baseline health care resource utilization questionnaire at screening in the ASCEND study 0881A3-402-WW from participating countries.
- Exclusion criteria:
- Withdrawal from the ASCEND study for safety or any other reason.
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00410046
Start Date
December 1 2006
End Date
October 1 2008
Last Update
May 11 2012
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Fredriksberg, Denmark, DK-2000
2
Odense, Denmark, DK-5000
3
Svendborg, Denmark, DK-5700
4
Vejle, Denmark, DK-7100